Journal of
neurology
neurosurgery
& psychiatry

EDITORIAL

Idiopathic intracranial hypertension: any light on the mechanism of the raised pressure?

Everyone knows that no one knows the mechanism of the increase of intracranial pressure in idiopathic intracranial hypertension (IIH; also called pseudotumour cerebri; see table 1 for diagnostic criteria). Does it much matter? After all, for most affected people IIH is a benign, self limiting condition. However, sometimes it is not,[1] and current therapies are unsatisfactory. Medical treatment is poor and of unproved benefit.[2 3] Surgical interventions (optic nerve sheath fenestration, lumboperitoneal shunting) have appreciable hazards and failure rates.[4–10] Moreover, the mechanism of increase in intracranial pressure in IIH might have relevance to raised intracranial pressure and its management in other situations such as meningitis and hydrocephalus.

Normal intracranial pressure

In normal circumstances intracranial pressure is maintained by cerebral arterial pressure which itself is subject to cerebral autoregulation such that, other things being equal, intracranial pressure remains constant over a wide range of systemic arterial blood pressure. Intracranial pressure is also greatly influenced by cerebral venous pressure. Furthermore, intracranial pressure is determined by CSF formation and absorption, but whether there are any physiological regulatory mechanisms operating at the choroid plexus or arachnoid villi and granulations is unclear. Pressure in CSF varies enormously in the lumbar region and at the vertex depending on posture (reviewed in Fishman[11]).

Increased intracranial pressure

At a simple level, various perturbations could lead to an increase in intracranial pressure without the development of hydrocephalus or florid visible abnormality on structural imaging. These are summarised in table 2. For any of these mechanisms to be operative, it is necessary that any compensatory processes are no longer functioning. Thus an increase in cerebral volume with an equivalent reduction in CSF volume will obviously not change the status quo. Over the years investigational techniques of every imaginable degree of complexity and invasiveness have been used to explore these possibilities in IIH. Many of the relevant indices such as CSF formation rate, CSF outflow resistance, CSF outflow rate, and sagittal sinus pressure can be measured or calculated, but some of the techniques used require certain assumptions and are therefore possibly fallible. Particular difficulties exist in knowing to what extent the brain is compressible in response to increasing CSF pressure, and to what extent the CSF space is expandable. These factors influence CSF outflow resistance calculations in infusion or perfusion studies.

Increased cerebral volume

Computed tomography offered a way of assessing cerebral volume in IIH, albeit somewhat crudely. A reduction in the size of the ventricular system, indicating an increase in cerebral volume, was reported in some studies,[12–14] but not in others,[15] and it remains controversial as to whether cerebral volume is significantly increased in IIH. The disagreement perhaps reflects heterogeneity of pathogenesis. The hope has been expressed that MRI will provide a great deal more information about what is going on in IIH, but thus far there has not been an abundance of reported studies of cerebral and CSF volumes in IIH, nor of the composition of cerebral tissue. Moser *et al*[16] reported an increase in white matter water signal, suggesting diffuse mild oedema, and Gideon *et al*[17] detected increased water mobility in subcortical white matter. Both studies required the use of special MRI sequences, routine sequences showing no abnormality. The brain in IIH has also been studied by positron emission tomography. Notably, no change in

Table 1 Modified Dandy criteria for IIH[3 79]

Symptoms and signs of increased ICP (headache, papilloedema)
No localising findings on neurological examination (except sixth cranial nerve lesion(s) or rarely other false localising signs)
Normal neuroimaging with no evidence of venous obstructive disease
Increased ICP as measured by lumbar puncture (>25 cm CSF)
Normal CSF constituents
Awake and alert patient
No other cause of increased ICP present
Benign clinical course apart from visual deterioration

ICP=Intracranial pressure.

Table 2 Perturbations which could lead to raised ICP

Increased cerebral volume	-increased ISF volume
	-increased blood volume
	-increased tissue volume
Increased CSF production rate	
Increased CSF outflow resistance	
Increased cerebral arterial pressure transmitted to capillaries (loss of autoregulation)	
Increased cerebral venous pressure	-leading to increased venous blood volume and increased ISF volume
	-leading to reduced CSF outflow

ISF=Interstitial fluid.

regional cerebral blood volume was found.[18] The most invasive studies of cerebral tissue in IIH were cerebral biopsies, which were reported by Sahs and Joynt[19] to show evidence of interstitial cerebral oedema, but necropsies[20] have not confirmed those findings, nor did a review of some of the original biopsy material of Sahs and Joynt.[20]

Increased CSF production

Increased CSF production rate has been proposed as a mechanism of IIH. The production rate of CSF can be measured in patients, but the procedures (infusion or perfusion techniques) are invasive.[21] In one study increased CSF production rate was reported in IIH.[22] However, most investigators have not found CSF hypersecretion in IIH. An attempt at measuring CSF production rate non-invasively by recording CSF flow through the cerebral aqueduct using MRI gave highly variable results, but again did not support the view that CSF hypersecretion is important in IIH.[23] The only condition in which the CSF production rate is known definitely to be increased is choroid plexus papilloma, a fairly rare paediatric tumour. With this tumour the situation can be complicated by obstructive hydrocephalus and hydrocephalus related to intraventricular haemorrhage. However, CSF overproduction has been proved in patients including one with a small non-obstructing tumour,[24 25] and it is presumptively part of the cause of the hydrocephalus. An IIH-like syndrome has not been reported in choroid plexus papilloma. Kollar and Johnson[26] used embolisation to treat an arteriovenous malformation which involved the great vein of Galen in a 5 year old child. After the successful occlusion, which was not complicated by venous thrombosis, the patient developed a pseudotumour syndrome, and the proposal was that a result of the procedure might have been an increase in CSF production by the choroid plexuses of the lateral ventricles as a result of change in venous pressure in the choroid plexuses. The CSF production rate, however, was not measured. There has been speculation that the benign intracranial hypertension associated with hypervitaminosis A might be due to CSF hypersecretion, but evidence is lacking.[27]

Idiopathic intracranial hypertension would require a generalised increase in intracranial pressure without a significant pressure gradient across the cortical mantle, and without any capacity for the brain to be compressed. Mathematical modelling of ventricular size in the circumstance of increased CSF production predicts hydrocephalus, not IIH.[28] Experimental infusion of artificial CSF into the lateral ventricles of dogs leads to modest ventricular enlargement, not an IIH-like syndrome.[29]

CSF outflow reduction

Much more important and relevant is the likelihood that impaired outflow of CSF into the venous system is a cause of IIH. However, herein lies a conundrum, as exactly the same mechanism is invoked to explain communicating hydrocephalus, including so called normal pressure hydrocephalus. In some studies the two groups of patients have even been analysed together, despite their striking clinical differences (for example, Borgesen and Gjerris[30]). An increase in CSF pressure, either due to CSF overproduction or due to impaired absorption, would be expected to lead to an increase in CSF volume, if the CSF space had the capacity for any expansion. Within a non-expansile skull and relatively non-expansile spinal canal, CSF could only easily accumulate at the expense of cerebral blood volume. In IIH there is neither a reduction in cerebral blood volume, nor an increase in CSF volume. In hydrocephalus, the main mechanism of ventricular dilatation is evidently a pressure difference between the

ventricular CSF and the convexity CSF, but pressure atrophy is also thought to play a part in the ventricular dilatation (see Fishman[11]). However, pressure atrophy does not seem to be operative in patients with chronic IIH, except possibly for two patients reported by Malm *et al*[31] who developed hydrocephalus after years of IIH. If the proposition is that the impairment of outflow of CSF is a lesion at the arachnoid villi and granulations level, then there is no reason to expect any transmantle pressure gradient, and it is easier to envisage this as a mechanism for IIH than NPH. Infants might represent a special case, as a non-acute increase in intracranial pressure may be expected to cause expansion of the skull vault, allowing the accumulation of CSF, either inside the ventricles or outside (external hydrocephalus). However, in the mathematical model of Rekate *et al*,[28] an increase in CSF outflow resistance alone leads to hydrocephalus, and to generate the conditions found in IIH a reduction in brain compressibility is required as well.

There is ample evidence from infusion and perfusion studies that IIH is associated with an impairment of outflow of CSF.[31–36] There is no direct evidence of dysfunction of arachnoid villi and granulations in IIH. Abnormalities of arachnoid villi have, however, been noted in certain conditions which involve raised intracranial pressure. Microscopy after subarachnoid haemorrhage has disclosed apparent obstruction of villi by cells and morphological changes in arachnoid villi and granulations.[37] The outflow resistance of CSF is known to be increased in experimental subarachnoid haemorrhage.[38] But the disturbance of CSF dynamics associated with subarachnoid haemorrhage is hydrocephalus, and the relevant site of CSF flow disturbance might be proximal to arachnoid villi and granulations. The same considerations apply to meningitis and experimental meningitis.[39] However, a pseudotumour syndrome is sometimes seen in the context of meningitis (see for instance Cremer *et al*[40]). Very high CSF protein concentration (spinal tumour, Guillain-Barré syndrome) is sometimes a cause of raised intracranial pressure with papilloedema,[41 42] and the suggestion has been made that the protein leads directly to impaired CSF outflow, and there is experimental evidence to support this.[43] Interestingly, some patients with raised intracranial pressure attributed to high CSF protein concentration from a spinal tumour develop hydrocephalus, and some have papilloedema without ventricular dilatation.[44] Agenesis, deficiency, or dysplasia of arachnoid villi and granulations leads to hydrocephalus in infancy.[45 46] (As indicated above, the capacity of the infant skull to expand may explain why hydrocephalus rather than a pseudotumour syndrome develops in this situation.) Vitamin A deficiency can cause a pseudotumour syndrome. Morphological abnormalities of arachnoid villi and granulations in experimental vitamin A deficiency have been described, and are presumably the cause of the increased CSF outflow resistance and the raised intracranial pressure.[47] Regrettably arachnoid villi and granulations were not available for histological examination in the two patients with IIH who came to necropsy and were reported by Wall *et al*.[20]

An apparent difficulty with the idea that IIH is caused by any sort of impairment of CSF outflow is the normal or even low CSF protein concentration in IIH.[48 49] The fluid which is made by the choroid plexuses is principally water and salt, with a low protein concentration. Protein gets into CSF diffusely throughout the system either from the brain and spinal cord parenchyma (mainly getting there across the blood-brain barrier) or directly across the blood-CSF barrier. Protein is absorbed into the venous system along with CSF. The gradient of CSF protein concentration (low in ventricular fluid and higher in lumbar fluid) is thus eas-

ily understood. In addition, the permeability of the blood-CSF barrier may be greater in the lumbar region.[11] An increase in CSF outflow resistance might be expected to involve an increase in CSF protein concentration, even if once a steady state is re-established the overall CSF turnover is unchanged. The low CSF protein concentrations sometimes found in IIH are measured in lumbar CSF, and a possible way of accounting for this would be an increase in CSF absorption at a spinal level in the face of an impairment of CSF absorption into the superior sagittal sinus (a proportion of CSF is absorbed by arachnoid villi and granulations which are in veins around spinal nerve roots). Low lumbar spinal fluid protein concentration would be compatible with a lesion affecting cerebral arachnoid villi and granulations selectively or preferentially. It would also be compatible with an increase in cerebral venous sinus pressure, but presumably not a global systemic increase in venous pressure which would affect spinal as well as cranial CSF absorption. Furthermore it would be compatible with an inverse relation between CSF protein concentration and intracranial hypertension. Such a relation was reported by Chandra *et al*,[49] but not confirmed by Johnston *et al*[48] in a larger study with more robust data.

Intracranial venous hypertension

The final candidate mechanism for IIH is the obvious one of an increase in venous sinus pressure—obvious because lesions which increase venous sinus pressure (for example, dural arteriovenous malformations) or impede venous drainage (for example, venous sinus thrombosis, malignant obstruction of venous sinuses or jugular veins) are known to give rise to the same syndrome as IIH.[50–53] Clearly superior sagittal sinus thrombosis will affect cerebral venous pressure and drainage and will also directly affect CSF absorption, but any disorder causing a rise in venous pressure will secondarily have an effect on CSF absorption.

In the CT era it is in fact quite likely that cases of cerebral venous sinus thrombosis were misdiagnosed as having IIH, as the diagnosis was often made on the basis of the clinical picture, an unremarkable scan and a lumbar puncture. Magnetic resonance imaging and magnetic resonance venography have improved the reliability of non-invasive detection of cerebral venous sinus thrombosis, but still some cases may be missed without catheter angiography or venography.[54 55] Recent reports of potentially prothrombotic abnormalities of coagulation in IIH[56–58] may be construed as indicating that undetected cerebral venous sinus thrombosis remains a mechanism of IIH, although other interpretations are possible.

Different groups have proposed that increased intracranial venous pressure is the major mechanism of raised intracranial pressure in IIH.[31 54 59 60] Malm *et al*[31] reported a long term study in which patients with IIH underwent repeated assessments of CSF hydrodynamics by means of a constant pressure infusion technique. In most of their patients raised CSF pressure could be explained by increased sagittal sinus pressure. Their hypothesis was that the increase in pressure in the superior sagittal sinus was secondary to cerebral swelling leading to a reduction of the diameter of the superior sagittal sinus, but as has been pointed out above brain swelling is not necessarily seen in IIH. Their other patients had raised pressure on the basis of reduced CSF outflow conductance, presumed to reflect a lesion at the arachnoid villi and granulations level.

In nine patients studied by King *et al*,[54] little abnormality was visible in the venous phase of cerebral angiograms, but manometry documented raised pressures in the superior sagittal sinuses and proximal transverse sinuses, with a drop in pressure in the distal transverse sinuses. Venography showed narrowing of the transverse sinuses, with either smooth tapering of uncertain cause, or intraluminal filling defects suggestive of mural thrombus. Of note were two patients whose intracranial hypertension was attributed to minocycline, who did not have raised venous sinus pressures, suggesting heterogeneity of pathogenesis. Subsequently King *et al*[61] reported briefly on a larger patient series. Fifteen out of 17 patients with IIH had raised superior sagittal sinus and proximal transverse sinus pressures with a drop in pressure in the distal transverse sinus. In four of these patients CSF was removed at the time of manometry with a resultant lowering of intracranial pressure, and that led to abolition of the apparent functional obstruction of the distal transverse sinus, which suggested to the authors that intracranial hypertension caused compression of the transverse sinus in some patients. This study highlights the possibility that increases in CSF pressure and venous pressure can interact so that each makes the other worse. The authors imply that they do not consider the increase in venous sinus pressure to be the primary event in most of their patients.

By contrast, Karahalios *et al*[59] speculated that "most if not all aetiologies (of IIH) result in an increase in intracranial venous pressure as a final common pathway." In their series venous outflow obstruction was detected by venography in five out of 10 patients studied. In the remaining five there was no obstruction but venous pressures were nevertheless increased, as were right atrial pressures with transmission of the raised central venous pressures back to the intracranial venous system. Karahalios *et al*[59] discuss ways in which obesity might lead to raised central venous pressures, but conclude that the mechanism of increased central venous pressure in IIH remains obscure.

No such doubts in the mind of Sugarman *et al*,[60 62 63] who contend that at least in morbidly obese persons pseudotumour cerebri is a direct result of obesity which leads to increased central venous and intracranial pressures (see below). Indeed they maintain that intracranial hypertension in this situation should no longer be considered idiopathic. In their hands gastric bypass surgery had a high success rate in resolution of symptoms of raised intracranial pressure (as well as treating joint problems, gastro-oesophageal reflux, high blood pressure, sleep apnoea, hypoventilation, diabetes, and urinary incontinence!). It might be speculated that increased venous pressure would affect cerebral compressibility in such a way as to favour a pseudotumour syndrome rather than hydrocephalus. Unexplained by this hypothesis is the absence of pseudotumour syndrome as a complication of right ventricular cardiac failure, although increased CSF pressure has been shown to accompany the rise of venous pressure which occurs in right heart failure.[64]

Obesity and IIH

The relation between IIH and obesity has long been recognised.[65–67] Pressure in the CSF is higher in obese but otherwise normal people than in people of normal weight.[68] An association between recent weight gain and the development of IIH has been established.[65 66] Weight reduction has long been part of the treatment strategy. There is some evidence that weight reduction is therapeutic. In two retrospective studies, Kupersmith *et al*[69] and Johnson *et al*[2] independently found that weight reduction was associated with improvement in[69] or resolution of[2] papilloedema in their patients. Rowe and Sarkies[70] on the other hand found no correlation between weight change and visual improvement in their series. Sugarman *et al*[60] reported on a series of eight morbidly obese patients with IIH, in all of whom gastric surgery for weight reduction was

successful in bringing about considerable weight reduction and also resolution of symptoms and signs of IIH including reduction of CSF pressure to normal.

How does obesity lead to an increase in intracranial pressure? Hormonal mechanisms have been postulated,[70] but Sugarman *et al*[62] have provided persuasive evidence in morbidly obese people for a simpler mechanism. They showed that their obese patients with IIH had raised intra-abdominal pressures, raised intrathoracic pressures, and raised central venous pressures, supporting a direct cause and effect relation. However, they did not have a satisfactory, concurrent control group, and did not provide an explanation as to why the pulmonary artery pressures were higher in their obese patients with IIH than in equivalently obese patients without IIH. It would be easy to diagnose this patient group as just having a pickwickian syndrome, but only two out of eight morbidly obese patients of Sugarman *et al*[60] had evidence of alveolar hypoventilation with reduced blood oxygen and raised blood carbon dioxide concentrations. Obesity is common, whereas IIH is rare, and obesity affects males as well as females, whereas IIH is much commoner in females than males, so obesity cannot be a sole cause of IIH, even though it may be the immediate cause in a suitably predisposed person. The established relation between obesity and IIH raises further questions. Although IIH in obese persons may be rare, headache in people of all shapes and sizes is very common, and the question does arise as to whether a proportion of obese persons with headache but without papilloedema in fact do have IIH. In the classic IIH series, papilloedema was present in 100% cases and was a diagnostic sine qua non.[71–74] However, it is not necessary to modify the Dandy criteria much further to open up a whole new vista of cases of overweight patients with bad headache and with high CSF pressures. Indeed, only 12 out of 24 patients had papilloedema in the updated series of Sugarman *et al*.[63] Several centres have published on IIH without papilloedema.[75–77] Disappointingly, the response of the patients to medication aimed at lowering intracranial pressure was poor.

Conclusion

It seems inescapable that the condition currently called IIH is heterogeneous, and indeed Johnston *et al*[78] proposed using the term pseudotumour syndrome to encompass this heterogeneity. In some patients there may be just one aetiology operating, such as occult venous sinus thrombosis. Perhaps others have risk factors which combine to precipitate the condition. In particular, in many cases obesity may be a risk factor whereas in extreme cases it may be a sufficient cause. Brain MRI really should be able to provide definitive information about cerebral and CSF volumes in IIH, but as yet the tunnel has not shed much light, and intriguing enigmas remain. Laboratory animal research, if possible, into factors influencing function of the arachnoid villi might well be informative. More effective means of preventing or treating obesity would undoubtedly have an impact on the prevention and treatment of IIH.

R W H WALKER

Department of Neurology, Barts and the London NHS Trust, The Royal London Hospital, Whitechapel, London E1 1BB, UK

1 Corbett JJ, Savino PJ, Thompson HS, *et al*. Visual loss in pseudotumor cerebri: follow up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. *Arch Neurol* 1982;**39**:461–74.
2 Johnson LN, Krohel GB, Madsen RW, *et al*. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). *Ophthalmology* 1998;**105**:2313–7.
3 Digre KB. Idiopathic intracranial hypertension. *Current treatment options in neurology* 1999;**1**:74–81.
4 Johnston I, Jacobson E, Besser M. Acquired Chiari malformation and syringomyelia following spinal CSF drainage: a study of incidence and management. *Acta Neurochir (Wien)* 1998;**140**:417–27.
5 Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri [see comments]. *Neurology* 1997;**49**:734–9.
6 Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. *Neurology* 1996;**46**:1524–30.
7 Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumour cerebri. *Arch Ophthalmol* 1993;**111**:632–5.
8 Corbett JJ, Nerad JA, Tse DT, *et al*. Results of optic nerve sheath fenestration for pseudotumour cerebri. *Arch Ophthalmol* 1988;**106**:1391–7.
9 Chumas PD, Armstrong DC, Drake JM, *et al*. Tonsillar herniation: the rule rather than the exception after lumboperitoneal shunting in the pediatric population. *J Neurosurg* 1993;**78**:568–73.
10 Payner TD, Prenger E, Berger TS, *et al*. Acquired Chiari malformations: incidence, diagnosis, and management. *Neurosurgery* 1994;**34**:429–34.
11 Fishman RA. *Cerebrospinal fluid in diseases of the nervous system*. 2nd ed. Philadelphia: WB Saunders, 1992.
12 Weisberg LA. Computed tomography in benign intracranial hypertension. *Neurology* 1985;**35**:1075–8.
13 Rothwell PM, Gibson RJ, Sellar RJ. Computed tomographic evidence of cerebral swelling in benign intracranial hypertension. *J Neurol Neurosurg Psychiatry* 1994;**57**:1407–9.
14 Reid AC, Matheson MS, Teasdale G. Volume of the ventricles in benign intracranial hypertension. *Lancet* 1980;ii:7–8.
15 Jacobson DM, Karanjia PN, Olson KA, *et al*. Computed tomography ventricular size has no predictive value in diagnosing pseudotumor cerebri. *Neurology* 1990;**40**:1454–5.
16 Moser FG, Hilal SK, Abrams G, *et al*. MR imaging of pseudotumor cerebri. *AJR Am J Roentgenol* 1988;**150**:903–9.
17 Gideon P, Sorensen PS, Thomsen C, *et al*. Increased brain water self-diffusion in patients with idiopathic intracranial hypertension. *Am J Neuroradiol* 1995;**16**:381–7.
18 Brooks DJ, Beaney RP, Leenders KL, *et al*. Regional cerebral oxygen utilization, blood flow, and blood volume in benign intracranial hypertension studied by positron emission tomography. *Neurology* 1985;**35**:1030–4.
19 Sahs AL, Joynt RJ. Brain swelling of unknown cause. *Neurology* 1956;**6**:791–803.
20 Wall M, Dollar JD, Sadun AA, *et al*. Idiopathic intracranial hypertension. Lack of histologic evidence for cerebral edema. *Arch Neurol* 1995;**52**:141–5.
21 Gjerris F, Borgesen SE. Current concepts of measurement of cerebrospinal fluid absorption and biomechanics of hydrocephalus. *Adv Tech Stand Neurosurg* 1992;**19**:145–77.
22 Donaldson JO. CSF hypersecretion in pseudotumor cerebri. *Trans Am Neurol Assoc* 1979;**104**:196–8.
23 Gideon P, Sorensen PS, Thomsen C, *et al*. Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. *Neuroradiology* 1994;**36**:350–4.
24 Eisenberg HM, McComb JG, Lorenzo AV. Cerebrospinal fluid overproduction and hydrocephalus associated with choroid plexus papilloma. *J Neurosurg* 1974;**40**:381–5.
25 Milhorat TH, Hammock MK, Davis DA, *et al*. Choroid plexus papilloma I. Proof of cerebrospinal fluid overproduction. *Child's Brain* 1976;**2**:273–89.
26 Kollar CD, Johnston IH. Pseudotumour after arteriovenous malformation embolisation [letter]. *J Neurol Neurosurg Psychiatry* 1999;**67**:249.
27 Fishman RA. The pathophysiology of pseudotumor cerebri: an unsolved puzzle. *Arch Neurol* 1984;**41**:257–8.
28 Rekate HL, Brodkey JA, Chizeck HJ, *et al*. Ventricular volume regulation: a mathematical model and computer simulation. *Pediatr Neurosci* 1988;**14**:77–84.
29 Rekate HL, Erwood S, Brodkey JA, *et al*. Etiology of ventriculomegaly in choroid plexus papilloma. *Pediatr Neurosci* 1986;**12**:196–201.
30 Borgesen SE, Gjerris F. Relationships between intracranial pressure, ventricular size, and resistance to CSF outflow. *J Neurosurg* 1987;**67**:535–9.
31 Malm J, Kristensen B, Markgren P, *et al*. CSF hydrodynamics in idiopathic intracranial hypertension: a long-term study. *Neurology* 1992;**42**:851–8.
32 Martins AN. Resistance to drainage of cerebrospinal fluid: clinical measurement and significance. *J Neurol Neurosurg Psychiatry* 1973;**36**:313–8.
33 Calabrese VP, Selhorst JB, Harbison JW. CSF infusion test in pseudotumor cerebri. *Trans Am Neurol Assoc* 1978;**103**:146–50.
34 Janny P, Chazal J, Colnet G, *et al*. Benign intracranial hypertension and disorders of CSF absorption. *Surg Neurol* 1981;**15**:168–74.
35 Sklar FH, Beyer CW, Ramanathan M, *et al*. Cerebrospinal fluid dynamics in patients with pseudotumor cerebri. *Neurosurgery* 1979;**5**:208–16.
36 Gjerris F, Sorensen PS, Vorstrup S, *et al*. Intracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension. *Ann Neurol* 1985;**17**:158–62.
37 Massicotte EM, Del Bigio MR. Human arachnoid villi response to subarachnoid hemorrhage: possible relationship to chronic hydrocephalus. *J Neurosurg* 1999;**91**:80–4.
38 Johnson RN, Maffeo CJ, Dacey RG, *et al*. Mechanism for intracranial hypertension during experimental subarachnoid hemorrhage: acute malfunction of arachnoid villi by components of plasma. *Trans Am Neurol Assoc* 1979;**103**:138–42.
39 Scheld WM, Dacey RG, Winn HR, *et al*. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. *J Clin Invest* 1980;**66**:243–53.
40 Cremer PD, Johnston IH, Halmagyi GM. Pseudotumour cerebri syndrome due to cryptococcal meningitis. *J Neurol Neurosurg Psychiatry* 1997;**62**:96–8.
41 Feldmann E, Bromfield E, Navia B, *et al*. Hydrocephalic dementia and spinal cord tumor. *Arch Neurol* 1986;**43**:714–8.
42 Ropper AH, Marmarou A. Mechanism of pseudotumor in Guillain-Barré syndrome. *Arch Neurol* 1984;**41**:259–61.
43 Prockop LD, Fishman RA. Experimental pneumococcal meningitis. Permeability changes influencing the concentration of sugars and macromolecules in cerebrospinal fluid. *Arch Neurol* 1968;**19**:449–63.
44 Ridsdale L, Moseley I. Thoracolumbar intraspinal tumours presenting features of raised intracranial pressure. *J Neurol Neurosurg Psychiatry* 1978;**41**:737–45.
45 Guttierez Y, Friede RL, Kaliney WJ. Agenesis of arachnoid granulations and its relationship to communicating hydrocephalus. *J Neurosurg* 1975;**43**:553–8.
46 Gilles FH, Davidson RI. Communicating hydrocephalus associated with deficient dysplastic parasagittal arachnoidal granulations. *J Neurosurg* 1971;**35**:421–6.
47 Hayes KC, McCombs HL, Faherty TP. The fine structure of vitamin A deficiency II. Arachnoid granulations and CSF pressure. *Brain* 1971;**94**:213–24.

48 Johnston PK, Corbett JJ, Maxner CE. Cerebrospinal fluid protein and opening pressure in idiopathic intracranial hypertension. *Neurology* 1991;**41**:1040–2.

49 Chandra V, Bellur SN, Anderson RL. Low CSF protein concentration in idiopathic pseudotumor cerebri. *Ann Neurol* 1986;**19**:80–2.

50 Cognard C, Casasco A, Toevi M, *et al*. Dural arteriovenous fistulas as a cause of intracranial hypertension due to impairment of cranial venous outflow. *J Neurol Neurosurg Psychiatry* 1998;**65**:308–16.

51 Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. *Neurology* 1999;**53**:1537–42.

52 Plant G, Donald JJ, Jackowski A, *et al*. Partial, non-thrombotic, superior sagittal sinus occlusion due to occipital skull tumours. *J Neurol Neurosurg Psychiatry* 1991;**54**:520–3.

53 Leker RR, Steiner I. Features of dural sinus thrombosis simulating pseudo-tumor cerebri. *Eur J Neurology* 1999;**6**:601–4.

54 King JO, Mitchell PJ, Thomson KR, *et al*. Cerebral venography and manometry in idiopathic intracranial hypertension. *Neurology* 1995;**45**:2224–8.

55 Cremer PD, Thompson EO, Johnston IH, *et al*. Pseudotumor cerebri and cerebral venous hypertension. *Neurology* 1996;**47**:1602–3.

56 Sussman J, Leach M, Greaves M, *et al*. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. *J Neurol Neurosurg Psychiatry* 1997;**62**:229–33.

57 Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. *Arch Neurol* 1998;**55**:817–20.

58 Kesler A, Ellis MH, Reshef T, *et al*. Idiopathic intracranial hypertension and anticardiolipin antibodies. *J Neurol Neurosurg Psychiatry* 2000;**68**:379–80.

59 Karahalios DG, Rekate HL, Khayata MH, *et al*. Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. *Neurology* 1996;**46**:198–202.

60 Sugerman HJ, Felton WL 3rd, Salvant JB, *et al*. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. *Neurology* 1995;**45**:1655–9.

61 King JO, Mitchell PJ, Thomson KR, *et al*. Cerebral venography and manometry in idiopathic intracranial hypertension [abstract]. *Neuroophthalmology* 1996;**16**:293.

62 Sugerman HJ, DeMaria EJ, Felton WL 3rd, *et al*. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. *Neurology* 1997;**49**:507–11.

63 Sugerman HJ, Felton WL 3rd, Sismanis A, *et al*. Gastric surgery for pseudo-tumor cerebri associated with severe obesity. *Ann Surg* 1999;**229**:634–40.

64 Friedfeld L, Fishberg AM. The relation of the cerebrospinal and venous pressures in heart failure. *J Clin Invest* 1934;**13**:495–501.

65 Ireland B, Corbett JJ, Wallace RB. The search for causes of idiopathic intracranial hypertension. *Arch Neurol* 1990;**47**:315–20.

66 Giuseffi V, Wall M, Siegel PZ, *et al*. Symptoms and disease associations in idiopathic intracranial hypertension: a case control study. *Neurology* 1991;**41**:239–44.

67 Radhakrishnan K, Ahlskog JE, Cross SA, *et al*. Idiopathic intracranial hypertension. Descriptive epidemiology in Rochester, Minn, 1976–90. *Arch Neurol* 1993;**50**:78–80.

68 Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. *Neurology* 1983;**33**:1386–8.

69 Kupersmith MJ, Gamell L, Turbin R, *et al*. Effects of weight loss on the course of idiopathic intracranial hypertension in women. *Neurology* 1998;**50**:1094–8.

70 Rowe FJ, Sarkies NJ. Visual outcome in a prospective study of idiopathic intracranial hypertension [letter]. *Arch Ophthalmol* 1999;**117**:1571

71 Weisberg LA. Benign intracranial hypertension. *Medicine* 1975;**54**:197–207.

72 Johnston I, Paterson A. Benign intracranial hypertension. I. Diagnosis and prognosis. *Brain* 1974;**97**:289–300.

73 Rush JA. Pseudotumor cerebri: clinical profile and visual outcome in 63 patients. *Mayo Clinic Proc* 1980;**55**:541–6.

74 Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. *Brain* 1991;**114**:155–80.

75 Marcelis J, Silberstein SD. Idiopathic intracranial hypertension without papilledema. *Arch Neurol* 1991;**48**:392–9.

76 Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idio-pathic intracranial hypertension without papilledema. *Neurology* 1996;**46**:1226–30.

77 Wang S, Silberstein SD, Patterson S, *et al*. Idiopathic intracranial hypertension without papilledema. A case control study in a headache center. *Neurology* 1998;**51**:245–9.

78 Johnston I, Hawke S, Halmagyi GM, *et al*. The pseudotumor syndrome. Disorders of cerebrospinal fluid circulation causing intracranial hypertension without ventriculomegaly. *Arch Neurol* 1991;**48**:740–7.

79 Sussman J, Sarkies NJ, Pickard JD. Benign intracranial hypertension. *Adv Tech Stand Neurosurg* 1998;**24**:261–305.

EDITORIAL COMMENTARIES

The volumes of memory

In 1937, Papez described a circuit for the processing of emotions, which has subsequently proved to be critical for memory function.[1] Various pathological entities can affect structures in this circuit, resulting in amnestic syndromes. In this issue of the *Journal* (pp 13–28), two related papers by Colchester *et al*[2] and Kopelman *et al*[3] used volumetric MR to assess the differing patterns of atrophy in patients with amnesia caused by several neurological diseases, and to examine the relation of these MR volumes to cognitive performance.

A great deal of recent work has focused on detecting atrophy in patients with neurodegenerative dementias, in particular Alzheimer's disease. Recent papers have reported significant atrophy in structures within the medial temporal lobe in memory impaired subjects even before the clinical diagnosis of Alzheimer's disease.[4–6] Relatively few studies have examined volumes of medial temporal lobe and other memory subserving structures in non-degenerative amnestic syndromes.

The report of Colchester *et al*[2] suggests that atrophy among the components of the circuit of Papez can be reliably quantified using MR volumetric assessment, and that amnestic syndromes of varying aetiology show specific patterns of atrophy. Of particular interest was the consistent finding of thalamic atrophy in the patients with Korsakoff's syndrome.

Complementing this work, Kopelman *et al*[3] examined the correlations between MR volumes of multiple brain regions and performance on several cognitive tests in patients with amnestic and other cognitive syndromes. Of note, the strongest relations were seen between hippocampal volume and anterograde memory measures, particularly evident in a factor analysis of the neuropsychological tests, although the thalamic measures did correlate with several memory tests.

These studies provide additional evidence for the critical role of the hippocampus in memory, and support the contribution of additional structures within the circuit of Papez to memory function. This work suggests that volumetric MR may be useful in elucidating the pattern of injury to neuroanatomical networks in various cognitive impairment syndromes.

R SPERLING

Brigham and Women's Hospital, Division of Cognitive and Behavioural Neurology, 221 Longwood Avenue, Boston MA 02115, USA
reisa@rics.bwh.harvard.edu

1 Papez JW. A proposed mechanism of emotion. *Arch Neurol Psychiatry* 1937;**38**:725–43.

2 Colchester A, Kingsley D, Lasserson D, *et al*. Structural MRI volumetric analysis in patients with organic amnesia, 1: methods and comparative findings across diagnostic groups. *J Neurol Neurosurg Psychiatry* 2001;**70**:13–22.

3 Kopelman MD, Lasserson D, Kingsley D, *et al*. Structural MRI volumetric analysis in patients with organic amnesia. 2: correlations with anterograde memory and executive tests in 40 patients. *J Neurol Neurosurg Psychiatry* 2001;**70**:23–28.

4 Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. *Lancet* 1999;**353**:2125.

5 Jack CR, Petersen RC, Xu YC, *et al*. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. *Neurology* 1999;**52**:1397–403.

6 Killiany RJ, Gomez-Isla T, Moss M, *et al*. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. *Ann Neurol* 2000;**47**:430–9.

EDITORIAL COMMENTARIES

Long term effects of locomotor training in spinal humans

A major concern for patients after spinal cord injury is whether or not they will ever walk again. For completely paralysed patients this prospect is slim, but the outlook for those with partial cord lesions is more hopeful. Any programme, such as that suggested in the paper by Wirz *et al* (this issue, pp 93–96), which may increase the likelihood of subsequent ambulation is to be welcomed.[1]

Control of locomotion in primates is predominantly supraspinal. In the thalamic macaque monkey electrical stimulation of the posterior subthalamic region or the midbrain tegmentum just ventral to the inferior colliculi produced stepping movements.[2] This was abolished in the suspended animal if the cord was completely transected, even when reflexes had returned. However, if pathways in the ventral white matter on one or both sides of the cord were spared, stepping and walking did occur.

Locomotor training of patients with unilateral lower limb paralysis supported over a moving treadmill was found to improve power in the paralysed limb to make walking possible with minimal splintage and this was attributed to enhancing spinal interneuronal locomotor networks.[3] However, as the ventral part of the cord was intact, at least in part, this improvement could equally well arise from the training of higher centres, if not also to continuing recovery in spinal neurons, although unlikely in those patients who had started training many years after injury.

When this locomotor training was applied to patients with complete spinal cord injury, only four out of 10 showed an EMG response.[4] The failure of the remainder to respond was attributed to the drugs they had been taking—the adrenoceptor antagonist prazosin or cannabis. Support for this was obtained by giving intrathecal adrenaline (epinephrine) which increased and clonidine which decreased motor performance. It could also be possible that those who responded may have had some tracts functioning that could not otherwise be detected by clinical or electrophysiological techniques, but nevertheless allowed conduction to supraspinal centres.

The present study shows that in the partially paralysed patients there was an improvement in the amplitude of gastrocnemius EMG on completion of the treadmill training which was still maintained a mean of 2 years later, especially as all these patients continued to walk during this time. The completely paralysed patients could not walk so the smaller improvement in gastrocnemius EMG was lost when they no longer received treadmill training. The improvement during training never reached functional levels in these patients and advocating such intensive treatment without showing a functional benefit could be psychologically harmful. There may be some benefit if these patients were to proceed to a functional electrical stimulation walking programme after discharge from the treadmill training.

As has been advocated, it is important to compare novel interventions in treatment with conventional techniques.[5] Many treadmill studies lack adequate spinal cord injury control groups to demonstrate the value of such training and although spinal interneuronal responses may be stimulated, the vital contribution of higher centres cannot be ignored. With some current research focused on spinal neuronal regeneration, such as by the transplant of oligodendroglia, olfactory, or Schwann cells, any technique to increase the functional capacity of the receiving circuits must surely be encouraged.

C G INMAN

Department of Spinal Injuries, Rookwood Hospital, Llandaff, Cardiff, and Department of Academic Surgery, University of Wales College of Medicine, Cardiff, Wales
clive.inman@UHW-TR.nhs.uk

1 Wirz M, Columbo G, Dietz V. Long term effects of locomotor training in humans. *J Neurol Neurosurg Psychiatry* 2001;**71**;93–6.
2 Eidelberg E, Walden JG, Nguyen LH. Locomotor control in macaque monkeys. *Brain* 1981;**104**:647–63.
3 Wernig A, Müller S. Laufband locomotion with body weight support improved walking in persons with severe spinal cord injuries. *Paraplegia* 1992;**30**:229–38.
4 Dietz V, Colombo G, Jensen L, *et al*. Locomotor capacity of spinal cord in paraplegic patients. *Ann Neurol* 1995;**37**:574–82.
5 Field-Fote EC. Spinal cord control of movement: implications for locomotor rehabilitation following spinal cord injury. *Phys Ther* 2000;**80**:477–84.

Cognitive function in the oldest old: women perform better than men

In the paper by van Exel *et al* in this issue (pp 29–32),[1] the authors examine the influence of sex and formal education on cognitive functioning in a community based sample of subjects over the age of 85. Based on the cognitive reserve theory of dementia, the authors hypothesise that women would be expected to score more poorly than men on cognitive tests due to a lower level of formal education.

Previous studies provide support for the theory that a lower educational level is a risk factor for the development of dementia.[2] This relation seems to be more pronounced

in female subjects than males,[3] although data regarding the influence of sex on cognitive functioning in non-demented persons were not available.

The results of the current study showed better cognitive performance in the female group, despite their lower level of formal education. One possible explanation raised by the authors was that medical risk factors (for example, atherosclerosis) may be greater in the male group. An alternative, or contributing factor, may be use of formal education as a measure of "cognitive reserve". Although years of education have traditionally been used to estimate premorbid functioning, some authors have suggested that formal education may be less important than later life experiences, such as primary occupation.[4] A follow up to the current study might examine the role of non-educational experiences on cognitive functioning between men and women.

This paper makes an important and timely contribution to the field of aging research, with the recent emphasis on early diagnosis of dementia. Understanding variables related to cognitive functioning in elderly people, such as the influence of sex, is essential for improving the ability to detect preclinical markers of dementia and identify "at risk" people who could benefit from clinical prevention trials.

N JOHNSON
Department of Psychiatry, Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Medical School, 320 EAST Superior Steet, Suite 11–499, Chicago, IL 60611–3010, USA

johnson-n@northwestern.edu

1 van Exel E, Gussekloo J, de Craen A J M, *et al*. Cognitive function in the oldest old: women perform better than men. *J Neurol Neurosurg Psychiatry* 2001;**70**:29–32.
2 Katzman R. Education and the prevalence of dementia and Alzheimer's disease. *Neurology* 1993;**43**:13–20.
3 Ott A, van Rossum CTM, van Harskamp F, *et al*. Education and the incidence of dementia in a large population-based study: The Rotterdam Study. *Neurology* 1999;**52**:663–6.
4 Stern Y, Alexander GE, Prohovnik I, *et al*. Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer's disease pathology. *Neurology* 1995;**45**:55–60.

1st Asia Pacific Forum on Quality Improvement in Health Care

Three day conference

Wednesday 19 to Friday 21 September 2001

Sydney, Australia

We are delighted to announce this forthcoming conference in Sydney. Authors are invited to submit papers (call for papers closes on Friday 6 April), and delegate enquiries are welcome.

The themes of the Forum are:
- Improving patient safety
- Leadership for improvement
- Consumers driving change
- Building capacity for change: measurement, education and human resources
- The context: incentives and barriers for change
- Improving health systems
- The evidence and scientific basis for quality improvement.

Presented to you by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA), with the support of the the Commonweatlh Department of Health and Aged Care (Australia), Safety and Quality Council (Australia), NSW Health (Australia) and Ministry of Health (New Zealand).

  For more information contact: quality@bma.org.uk or fax +44 (0) 7383 6869